BioXcel Therapeutics, Inc. Research and Development Expense
BioXcel Therapeutics, Inc. (BTAI) reported Research and Development Expense of $3.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- BioXcel Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $3.16M, a 69.15% decline year-over-year.
- BioXcel Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $2.96M, a 35.11% decline year-over-year.
- BioXcel Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $6.70M, a 13.56% increase year-over-year.
- BioXcel Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $8.74M, a 71.34% increase year-over-year.
- BioXcel Therapeutics, Inc. research and development expense for fiscal 2025 was $30.25M, a 0.60% decline from fiscal 2024.
- BioXcel Therapeutics, Inc. research and development expense for fiscal 2024 was $30.43M, a 63.91% decline from fiscal 2023.
- BioXcel Therapeutics, Inc. research and development expense for fiscal 2023 was $84.33M, a 7.58% decline from fiscal 2022.
- BioXcel Therapeutics, Inc. research and development expense for fiscal 2022 was $91.24M, a 73.10% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.16M 10-Q · filed 2026-08-13 | $6.12M 10-Q · filed 2026-08-13 | $12.82M derived: sum of 3 quarters · filed 2026-08-13 | $21.56M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.96M 10-Q · filed 2026-05-15 | $9.66M derived: sum of 2 quarters · filed 2026-05-15 | $18.40M derived: sum of 3 quarters · filed 2026-05-15 | $28.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $6.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $15.44M derived: sum of 2 quarters · filed 2026-03-27 | $25.70M derived: sum of 3 quarters · filed 2026-08-13 | $30.25M 10-K · filed 2026-03-27 |
| 2025-09-30 | $8.74M 10-Q · filed 2025-11-12 | $19.00M derived: sum of 2 quarters · filed 2026-08-13 | $23.55M 10-Q · filed 2025-11-12 | $29.45M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $10.26M 10-Q · filed 2026-08-13 | $14.81M 10-Q · filed 2026-08-13 | $20.71M derived: sum of 3 quarters · filed 2026-08-13 | $25.81M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $4.55M 10-Q · filed 2026-05-15 | $10.46M derived: sum of 2 quarters · filed 2026-05-15 | $15.56M derived: sum of 3 quarters · filed 2026-05-15 | $23.59M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $5.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $11.00M derived: sum of 2 quarters · filed 2026-03-27 | $19.03M derived: sum of 3 quarters · filed 2026-03-27 | $30.43M 10-K · filed 2026-03-27 |
| 2024-09-30 | $5.10M 10-Q · filed 2025-11-12 | $13.13M derived: sum of 2 quarters · filed 2025-11-12 | $24.53M 10-Q · filed 2025-11-12 | $34.47M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $8.03M 10-Q · filed 2025-08-12 | $19.43M 10-Q · filed 2025-08-12 | $29.37M derived: sum of 3 quarters · filed 2025-08-12 | $48.99M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $11.40M 10-Q · filed 2025-05-12 | $21.34M derived: sum of 2 quarters · filed 2025-05-12 | $40.95M derived: sum of 3 quarters · filed 2025-05-12 | $67.93M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $9.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $29.55M derived: sum of 2 quarters · filed 2025-03-28 | $56.53M derived: sum of 3 quarters · filed 2025-03-28 | $84.33M 10-K · filed 2025-03-28 |
| 2023-09-30 | $19.62M 10-Q · filed 2024-11-14 | $46.59M derived: sum of 2 quarters · filed 2024-11-14 | $74.39M 10-Q · filed 2024-11-14 | $106.85M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $26.97M 10-Q · filed 2024-08-06 | $54.77M 10-Q · filed 2024-08-06 | $87.23M derived: sum of 3 quarters · filed 2024-08-06 | $109.29M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $27.80M 10-Q · filed 2024-05-09 | $60.26M derived: sum of 2 quarters · filed 2024-05-09 | $82.32M derived: sum of 3 quarters · filed 2024-05-09 | $100.23M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $32.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $54.52M derived: sum of 2 quarters · filed 2024-03-22 | $72.43M derived: sum of 3 quarters · filed 2024-03-22 | $91.24M 10-K · filed 2024-03-22 |
| 2022-09-30 | $22.06M 10-Q · filed 2023-11-14 | $39.97M derived: sum of 2 quarters · filed 2023-11-14 | $58.78M 10-Q · filed 2023-11-14 | $71.05M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $17.91M 10-Q · filed 2023-08-14 | $36.59M 10-Q · filed 2023-08-14 | $48.99M derived: sum of 3 quarters · filed 2023-08-14 | $60.92M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $18.56M 10-Q · filed 2023-05-09 | $31.08M derived: sum of 2 quarters · filed 2023-05-09 | $43.02M derived: sum of 3 quarters · filed 2023-05-09 | $56.53M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $12.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $24.46M derived: sum of 2 quarters · filed 2023-03-16 | $37.97M derived: sum of 3 quarters · filed 2023-03-16 | $52.71M 10-K · filed 2023-03-16 |
| 2021-09-30 | $11.93M 10-Q · filed 2022-11-14 | $25.44M derived: sum of 2 quarters · filed 2022-11-14 | $40.18M 10-Q · filed 2022-11-14 | $51.58M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $13.51M 10-Q · filed 2022-08-11 | $28.25M 10-Q · filed 2022-08-11 | $39.65M derived: sum of 3 quarters · filed 2022-08-11 | $55.97M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $14.74M 10-Q · filed 2022-05-09 | $26.14M derived: sum of 2 quarters · filed 2022-05-09 | $42.46M derived: sum of 3 quarters · filed 2022-05-09 | $60.36M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $11.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $27.72M derived: sum of 2 quarters · filed 2022-03-11 | $45.62M derived: sum of 3 quarters · filed 2022-03-11 | $57.99M 10-K · filed 2022-03-11 |
| 2020-09-30 | $16.32M 10-Q · filed 2021-11-10 | $34.22M derived: sum of 2 quarters · filed 2021-11-10 | $46.59M 10-Q · filed 2021-11-10 | $53.09M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $17.91M 10-Q · filed 2021-08-10 | $30.28M 10-Q · filed 2021-08-10 | $36.77M derived: sum of 3 quarters · filed 2021-08-10 | $43.89M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $12.37M 10-Q · filed 2021-05-10 | $18.87M derived: sum of 2 quarters · filed 2021-05-10 | $25.99M derived: sum of 3 quarters · filed 2021-05-10 | $32.49M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $6.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $13.62M derived: sum of 2 quarters · filed 2021-03-12 | $20.12M derived: sum of 3 quarters · filed 2021-03-12 | $25.80M 10-K · filed 2021-03-12 |
| 2019-09-30 | $7.12M 10-Q · filed 2020-11-12 | $13.63M derived: sum of 2 quarters · filed 2020-11-12 | $19.30M 10-Q · filed 2020-11-12 | $25.32M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $6.51M 10-Q · filed 2020-08-14 | $12.18M 10-Q · filed 2020-08-14 | $18.20M derived: sum of 3 quarters · filed 2020-08-14 | $22.02M derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | $5.67M 10-Q · filed 2020-05-12 | $11.69M derived: sum of 2 quarters · filed 2020-05-12 | $15.51M derived: sum of 3 quarters · filed 2020-05-12 | $17.29M derived: sum of 4 quarters · filed 2020-05-12 |
| 2018-12-31 | $6.02M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $9.84M derived: sum of 2 quarters · filed 2020-03-09 | $11.62M derived: sum of 3 quarters · filed 2020-03-09 | $14.56M 10-K · filed 2020-03-09 |
| 2018-09-30 | $3.82M 10-Q · filed 2019-11-14 | $5.60M derived: sum of 2 quarters · filed 2019-11-14 | $8.54M 10-Q · filed 2019-11-14 | $9.97M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $1.78M 10-Q · filed 2019-08-06 | $4.72M 10-Q · filed 2019-08-06 | $6.14M derived: sum of 3 quarters · filed 2019-08-06 | $6.76M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $2.94M 10-Q · filed 2019-05-07 | $4.36M derived: sum of 2 quarters · filed 2019-05-07 | $4.98M derived: sum of 3 quarters · filed 2019-05-07 | $5.31M derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $2.04M derived: sum of 2 quarters · filed 2019-03-12 | $2.37M derived: sum of 3 quarters · filed 2019-03-12 | $2.69M 10-K · filed 2019-03-12 |
| 2017-09-30 | $619.00K 10-Q · filed 2018-11-09 | $943.00K derived: sum of 2 quarters · filed 2018-11-09 | $1.26M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $324.00K 10-Q · filed 2018-08-08 | $645.00K 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $321.00K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |